|
|
||||||||
J. Biol. Chem., Vol. 277, Issue 25, 22484-22490, June 21, 2002
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
From the Faculty of Bioscience and Biotechnology and
Received for publication, March 29, 2002
The transcription factor hGABP/E4TF1 is a
heterotetrameric complex composed of two DNA-binding subunits
(hGABP E4TF1 was originally purified from HeLa cells and was identified
as one of the sequence-specific transcription factors that bind to and
stimulate transcription from the adenovirus early 4 (E4)1 promoter (1, 2).
Subsequent cDNA cloning and nucleotide sequence analyses (3, 4)
have revealed that it is a human homologue of the rat GA-binding
protein (hGABP), which binds to the GA motif of the herpes simplex
virus immediate early genes and stimulates their transcription (5,
6).
E4TF1/hGABP is a unique transcription factor in its subunit
composition. It is a heterotetramer
( In addition to the adenovirus E4 gene and the herpes simplex virus
immediate early genes, an increasing number of cellular genes have been
found to be targets of E4TF1/hGABP. In accordance with the fact that
E4TF1/hGABP is a ubiquitously expressed transcription factor, its
targets include ubiquitously expressed genes such as the genes for
cytochrome c oxidase subunits IV and Vb (9), the ATP
synthase One of the most likely control mechanisms of such transcriptional
regulation is an interaction with other transcription factors. In fact,
we and others have demonstrated that E4TF1/hGABP synergistically activates transcription through physical interaction with the ATF1,
CREB (21), SP1 (22), SP3 (23), and HCF transcription factors (24). In
contrast, E4TF1/hGABP activity is inhibited by interaction with
the mi transcription factor (MITF) in mast cells
(25).
To understand the mechanism of transcriptional regulation by
E4TF1/hGABP, it is important to clarify the regulatory cross-talk that
occurs with other transcription factors and cofactors. To this end, we
screened a cDNA expression library for genes whose products
interact with the hGABP Yeast Two-hybrid Screening and Interaction Assay--
A yeast
two-hybrid screen was performed using a modified version of the system
of Fields and Song (27). Briefly, pBTM116/hGABP
For the interaction assay, the L40 yeast strain was transformed with an
appropriate LexA fusion plasmid and GAL4-activation domain fusion
plasmid (pGAD424; CLONTECH) and was plated onto a
selective medium (
For three-hybrid assay, pBridge Three-Hybrid Vector
(CLONTECH) was used to express GAL4-DNA-binding
domain fusion and bridge proteins. The expression of the bridge protein
can be inhibited by addition of methionine into the medium.
Plasmids--
LexA fusion or GAL4-activation domain fusion
plasmids used for yeast two-hybrid interaction assays were constructed
by insertion of PCR-amplified fragments into appropriate sites of
pBTM116 (a generous gift of Dr. Hollenberg) or pGAD424
(CLONTECH), respectively. A human YY1 cDNA (28)
was a gift from Dr. T. Shenk. A human YAF-2 cDNA was obtained by
screening a HeLa cDNA library using a YEAF1 cDNA probe.
Surface Plasmon Resonance Analysis--
An
EcoRI-XhoI fragment containing a full-length
YEAF1 open reading frame was excised from pGAD424/YEAF1 and inserted
into EcoRI/XhoI-digested pGEX5X3 to make
pGEX5X3/YEAF1. A glutathione S-transferase (GST)-YEAF1
protein was expressed in E. coli BL21 (DE3) and purified.
GST-YEAF1 was then immobilized onto Sensor Chip CM5 (Biacore AB)
(~2500 resonance units) via an anti-GST antibody, and the chip was
used to analyze the interaction using BIACORE2000 as described
previously (8). Recombinant hGABP Immunoprecipitation and Western Blotting--
A mammalian
expression plasmid for FLAG-tagged YEAF1 was constructed by inserting a
FLAG sequence and YEAF1 cDNA fragment into a pCAGGS vector. Four
micrograms of the resultant plasmid pCAGGS/FLAG-YEAF1 or of
pCAGGS/FLAG, which expresses the FLAG peptide only, was transfected
into 1 × 105 HeLa cells in a 100-mm dish using the
Effectene reagent (Qiagen). Forty eight hours after transfection, cells
were lysed with 500 µl of lysis buffer (20 mM HEPES, pH
7.9, 50 mM KCl, 10 µM ZnSO4, 1 mM phenylmethylsulfonyl fluoride, 1 µg/ml pepstatin,
1.0% Nonidet P-40). The total cell extract (400 µl) was incubated
with 20 µl of anti-FLAG M2 antibody-conjugated resin (Sigma) for
8 h at 4 °C, and the resin was washed three times with wash
buffer (20 mM HEPES, pH 7.9, 50 mM KCl, 10 µM ZnSO4, 1 mM
phenylmethylsulfonyl fluoride, 1 µg/ml pepstatin, 0.01% Nonidet
P-40). The precipitated complex was eluted by boiling the resin in 40 µl of SDS sample buffer. The eluate and the total cell extract were
separated on a 10% SDS-polyacrylamide gel, transferred to a
polyvinylidene difluoride membrane, and stained with monoclonal mouse
anti-FLAG (Sigma), monoclonal mouse anti-hGABP Luciferase Assay--
Transfection of Schneider's 2 (SL2)
Drosophila melanogaster cells, the luciferase assay, and the
Northern Blot Analysis--
A human multiple tissue
Northern blot (CLONTECH) was hybridized with
32P-labeled YEAF1, YAF-2, hGABP Isolation of YEAF1, a Novel Factor Interacting with the hGABP
By plaque hybridization using this partial cDNA fragment as a probe
and 3'-rapid amplification of cDNA ends, we obtained a cDNA
contig of 4765 bp (data not shown, GenBankTM accession
number AB029551). The cDNA contig (designated as YY1
and E4TF1/hGABP associated factor-1 (YEAF1),
see below) contained a putative poly(A) addition signal and poly(A)
stretch at the 3' end of the cDNA and two ATG codons at the 5' end
of its single open reading frame. We speculated that the second ATG
codon might be the initiator codon, because it showed similarity to the
putative initiator codon of YAF-2 (26), and its
surrounding sequence completely matches the Kozak's consensus
sequence. Based on this information and the mRNA length predicted
from a Northern blot analysis (5.0 kb, see below), we believe that we
obtained nearly full-length cDNA. The YEAF1 protein contained no
significant protein motif other than two potential zinc fingers at its
amino-terminal region (Fig.
1A).
As mentioned above, the protein was similar to the YAF-2 protein (Fig.
1A) reported previously (26). YEAF1 and YAF-2 shared the
highest homology at the amino-terminal domain containing the two zinc
finger motifs and moderate similarity at the carboxyl-terminal domain,
which we refer to as conserved region (CR) 1 and 2, respectively (Fig.
1B). YEAF1 also contains a unique region between CR1 and CR2
that is absent in YAF-2, and we refer to this as the YEAF1 original
region (OR) (Fig. 1B). Later on, YEAF1 was found to be highly homologous to mouse RYBP (Ring1 and
YY1-binding protein) (29),
indicating that YEAF1 and RYBP are species homologues.
YEAF1 Interacts with Both hGABP
In contrast, the LexA fusion of the DNA-binding subunit hGABP
We also found that YEAF1 interacts with YY1 (Fig. 2B), as
would be expected based on its similarity to YAF-2, which was
originally identified as an interacting partner of YY1 (26). Therefore, YEAF1 interacts with both hGABP hGABP
The fact that the CR2 of YEAF1 has sequence similarity with the
corresponding region of YAF-2 prompted us to test the interaction of
YAF-2 and hGABP Kinetic Analysis of Binding of YEAF1 with hGABP
We also analyzed the interaction between hGABP Interaction of YEAF1 with Both hGABP and YY1 in Vivo--
To test
whether YEAF1 forms a functional complex with hGABP
We then prepared nuclear extracts from the transfected cells and
subjected them to immunoprecipitation using the anti-FLAG antibody.
Aliquots of the precipitate were analyzed by immunoblotting with
anti-FLAG, anti-hGABP Ternary Complex Formation of hGABP, YEAF1, and YY1--
The result
shown above does not necessarily indicate that hGABP, YEAF1, and YY1
form a ternary complex. To test this possibility, we performed a yeast
three-hybrid assay schematically show in Fig.
6A. In addition to the GAL4DB
and GAL4AD fusion proteins, the third protein ("bridge" protein) is
expressed in yeast to test a ternary complex formation. The expression
of the bridge protein can be down-regulated by addition of methionine
into the medium.
The background
We further showed that hGABP YEAF1 Repressed and YAF-2 Stimulated Transcriptional Activity of
hGABP--
We next examined the effects of YEAF1 and YAF-2 on the
biological activity of hGABP. To this end, we measured transcriptional activity of hGABP by transient transfection and a luciferase assay. We
used a human retinoblastoma (Rb) gene promoter-luciferase construct (pRb-luciferase) as a reporter (Fig.
7A) and the D. melanogaster Schneider's line 2 (SL2) cell line as a recipient
cell, because the Rb promoter contains an hGABP-binding site (12, 13),
and SL2 cells contain little endogenous hGABP-like activity (7). As we
have reported previously (7), transfection of an expression plasmid
containing the DNA-binding subunit hGABP
In contrast to YEAF1, the transcriptional activity of hGABP was
enhanced by co-transfection of an increasing amount of YAF-2, indicating that YAF-2 acts as a transcriptional co-activator for hGABP
(Fig. 7C). Therefore, YEAF1 and YAF-2 exhibited opposite effects on the transcriptional activity of hGABP, despite being structurally related.
Tissue Distribution of YEAF1, YAF-2, and hGABP In this paper, we described the isolation and characterization of
YEAF1, a novel interactor of the hGABP/E4TF1 transcription factor. We
demonstrated that YEAF1 and its close relative YAF-2 also interact with
another transcription factor YY1 and that they act as bridging factors
for GABP and YY1. Despite their structural similarity, YEAF1 and YAF-2
were functionally distinct, in that YEAF1 negatively regulated the
transcriptional activity of hGABP but YAF-2 positively regulated the activity.
We demonstrated here that YEAF1 and YAF-2 constitute a family of
cofactors for the hGABP and YY1 transcription factors. The first
identified member, YAF-2, was originally isolated as a factor interacting with YY1 in yeast two-hybrid screening (26). As expected
from their sequence similarity, we showed that YEAF1 also interacts
with YY1, and YAF-2 interacts with hGABP We did not find any other family members of YEAF1 and YAF-2 in a search
of the human genome using the GenBankTM data base, but we
did identify homologous putative genes, CG12190 and
C54H2.3, in the D. melanogaster and
Caenorhabditis elegans genomes,
respectively,2 suggesting
that they are evolutionarily conserved at least among multicellular organisms.
YEAF1 is the human homologue of the mouse RYBP. RYBP was isolated as an
interacting partner of Ring1A protein, a member of the Polycomb group
(PcG) of proteins (29). The PcG proteins form large complexes that are
necessary for the maintenance of the transcriptionally repressed state
of a number of genes. It has been shown that RYBP also interacts with
another PcG protein, M33, a mouse homologue of Drosophila
polycomb (Pc), and with YY1 (29). YY1 has similarity to
the Drosophila pleiohomeotic (pho) gene product
(30), and accumulating evidence suggests that YY1 is also involved in
PcG function (29, 31). Thus, RYBP is considered to be a component of
PcG complexes and accordingly acts as a transcriptional repressor when
fused with the DNA-binding domain of the GAL4 transcription factor
(29). The most plausible model of the repressor function of YEAF1/RYBP
is that they recruit PcG complexes. This idea is supported by the
recent report (32) that RYBP interacts with the repressor domain of
E2F6, a distantly related member of the E2F transcription factors. E2F6
has been shown to form complexes with other PcG proteins such as Ring1,
Bmi1, MEL-18, and Mph1.
We demonstrated here that YEAF1 binds to hGABP and represses its
transcriptional activity. Therefore, YEAF1/RYBP mediates the
transcriptional repression of at least two sequence-specific DNA-binding factors, E2F6 and hGABP. YY1 may also be the target of
YEAF1 repression because YY1 can act as a transcriptional repressor depending on the promoter context. It seems consistent that E2F6 (and
possibly YY1) actively represses transcription by interacting with PcG
complexes. In contrast to E2F6 and YY1, such an active repressor
function or active repressor domain has never been assigned to
hGABP Despite the similar affinity of YEAF1 and YAF-2 for hGABP We further showed that both hGABP, YEAF1, and YY1 form a ternary
complex. As both hGABP and YY1 are sequence-specific DNA-binding proteins, YEAF1 (and probably YAF-2) should be able to bridge hGABP and
YY1 when they bind to DNA. It is noteworthy that some promoters contain
binding sites for both the hGABP and YY1 transcription factors. For
example, the P6 promoter of the human B19 parvovirus contains adjacent
hGABP- and YY1-binding sites (33). The activity of this promoter was
activated by hGABP and repressed by YY1. Because YEAF1/RYBP is a
component of PcG complexes (29), binding of YY1 to the promoter may
recruit YEAF1 and PcG complexes to hGABP, which may result in
transcriptional repression. This may be not the case for cytochrome
c oxidase subunit genes (34), whose promoter regions also
contain binding sites for hGABP and YY1, but both of which in this case
have been shown to be necessary for efficient transcription. One
can speculate that bridging by YAF-2 may enhance transcription by hGABP
and YY1. However, a more detailed analysis of the regulation of such
promoters is necessary to understand the mechanism of positive and
negative regulation by hGABP and YY1. Isolation and characterization of
the functionally distinct bridging factors YEAF1 and YAF-2 described
here may elucidate the molecular mechanisms of transcriptional
regulation by hGABP and YY1, as well as by PcG complexes.
We are grateful to S. M. Hollenberg for
gifts of the yeast strains and the plasmid pBTM116 and its derivatives
and to Dr. T. Yamamoto for assistance with the yeast procedures. We
thank T. Shenk for the gift of YY1 cDNA. We also thank Drs. T. Wada and T. Imai for helpful discussions and advice.
*
This work was supported by a grant-in-aid for Scientific
Research on Priority Areas from the Ministry of Education, Culture, Sports, Science and Technology and by a grant for Research and Development Projects in cooperation with Academic Institutions from the
New Energy and Industrial Technology and Development Organization.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
¶
Present address: Dept. of Cancer Biology, Dana-Farber Cancer
Institute, Boston, MA 02115.
**
To whom correspondence should be addressed: Frontier Collaborative
Research Center, Tokyo Institute of Technology, 4259 Nagatsuta-cho, Midori-ku, Yokohama 226-8501, Japan. Tel.: 81-45-924-5872; Fax: 81-45-924-5145; E-mail: hhanda@bio.titech.ac.jp.
Published, JBC Papers in Press, April 12, 2002, DOI 10.1074/jbc. M203060200
2
C. Sawa, T. Yoshikawa, F. Matsuda-Suzuki,
S. Deléhouzée, M. Goto, H. Watanabe, J.-i. Sawada, K. Kataoka, and H. Handa, unpublished observations.
The abbreviations used are:
E4, adenovirus early
4;
YY1, Ying-Yang-1;
YAF-2, YY1-associated factor 2;
hGABP, human
GA-binding protein;
YEAF1, YY1- and E4TF1/hGABP-associated factor-1;
RYBP, Ring1 and YY1 binding protein;
3-AT, 3-aminotriazol;
GST, Glutathione S-transferase;
Rb, retinoblastoma susceptibility gene;
CR, conserved region, OR, original region;
SPR, surface plasmon resonance;
PcG, Polycomb group.
YEAF1/RYBP and YAF-2 Are Functionally Distinct Members of a
Cofactor Family for the YY1 and E4TF1/hGABP Transcription
Factors*
,
, and
**
Frontier Collaborative Research Center, Tokyo Institute of
Technology, 4259 Nagatsuta-cho, Midori-ku, Yokohama 226-8501 and
§ National Institute for Basic Biology, Okazaki National
Research Institutes, 38 Myodaiji, Okazaki 444-8585, Japan
![]()
ABSTRACT
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
/E4TF1-60) and two transactivating subunits
(hGABP
/E4TF1-53). In order to understand the molecular mechanism of
transcriptional regulation by hGABP, we searched for proteins that
interact with the non-DNA-binding subunit, hGABP
, using yeast
two-hybrid screening. We identified a human cDNA encoding a protein
related to YAF-2 (YY1-associated factor 2), which was previously
isolated as an interacting partner of the Ying-Yang-1 (YY1)
transcription factor. Reflecting this similarity, both YAF-2 and this
novel protein (named YEAF1 for YY1- and
E4TF1/hGABP-associated
factor-1) interacted with hGABP
and YY1
in vitro and in vivo, indicating that YEAF1 and
YAF-2 constitute a cofactor family for these two structurally distinct transcription factors. By using yeast three-hybrid assay, we
demonstrated that hGABP
and YY1 formed a complex only in the
presence of YEAF1, indicating that YEAF1 is a bridging factor of these
two transcription factors. These cofactors are functionally different
in that YAF-2 positively regulates the transcriptional activity of
hGABP but YEAF1 negatively regulates this activity. Also,
YAF-2 mRNA is highly expressed in skeletal muscle,
whereas YEAF1 mRNA is highly expressed in placenta. We
speculate that the transcriptional activity of hGABP is in part
regulated by the expression levels of these tissue-specific cofactors.
These results provide a novel mechanism of transcriptional regulation
by functionally distinct cofactor family members.
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
2
2) of two 60-kDa
(E4TF1-60/hGABP
) and two 53-kDa (E4TF1-53/hGABP
) subunits.
Structural and biochemical analyses (3, 4, 7, 8) have revealed that
hGABP
contains an Ets-related DNA-binding domain and can bind to the
DNA sequence 5'-CGGAAGTG-3'. However, hGABP
alone is unable to
activate transcription, and the transactivator function is conferred by
the formation of a heterotetramer with hGABP
. In contrast to
hGABP
, hGABP
alone cannot bind to DNA, but it forms a homodimer
through its leucine zipper-like structure at the carboxyl terminus and
forms a heterodimer with hGABP
through its Notch/ankyrin repeat
motif at the amino terminus. The resultant
2
2 heterotetramer has the capacity
to activate transcription. Another non-DNA-binding subunit of 47 kDa,
E4TF1-47/GABP
, is structurally identical to hGABP
except that it
differs at its carboxyl extremity and lacks the homodimerization
domain. GABP
retains the ability to form a heterodimer with hGABP
but the resultant 
heterodimer cannot activate transcription. The
subunit composition is therefore one mechanism for the regulation of
the transcriptional activity of hGABP (4, 7, 8).
-subunit (10), ribosomal proteins L30 and L32 (11), and the
retinoblastoma tumor suppressor protein (12, 13). However, some
tissue-specific genes, such as male-specific steroid 16
-hydroxylase
(14), leukocyte-specific cell adhesion molecule CD18
(
2 integrin) (15), neutrophil elastase (16), interleukin-2 (17), utrophin (18, 19), and nicotinic acetylcholine receptor subunits (20), have also been demonstrated to be regulated by
E4TF1/hGABP. Despite accumulating evidence for both ubiquitous and
tissue-specific gene regulation by E4TF1/hGABP, how this regulation is
achieved is still unknown.
subunit, and we isolated a cofactor, YEAF1/RYBP. We demonstrate here that YEAF1/RYBP represses the transcriptional activity of E4TF1/hGABP, whereas its close relative, YAF-2 (26), activates the activity of E4TF1/hGABP. These results provide the first example of a cofactor family with functionally distinct members.
![]()
MATERIALS AND METHODS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
-(249-383), encoding a LexA-fusion protein with amino acids 249-383 of hGABP
, was transformed into the yeast strain L40 by the lithium acetate method. The resultant strain was then transformed with a
GAL4-activation domain fusion cDNA library constructed from
mRNAs of HeLa cells (MATCHMAKER HL4000AA,
CLONTECH). The transformants were plated onto a
selective medium for histidine prototrophy (
Trp,
Leu,
Ura,
Lys,
His, and 10 mM 3-aminotriazole (3-AT)) and were incubated at 30 °C for 5 days. His+ colonies were then grown in a liquid selective (
Trp,
Leu) medium until the
A600 reached 1.0 to 1.2 and were further
tested for
-galactosidase activity as described previously (13).
Each GAL4 fusion prey plasmid was rescued from the 3-AT-resistant and
-galactosidase-positive yeast clones and transformed into
Escherichia coli (DH5
).
Trp,
Leu). Three independent transformed colonies
were then assayed for 3-AT sensitivity and
-galactosidase activity.
and hGABP
proteins expressed in
E. coli were prepared as described previously (3).
, or polyclonal rabbit
anti-YY1 (Santa Cruz Biotechnology) antibodies using ECL detection
reagents (Amersham Biosciences).
-galactosidase assay were performed as described previously (7). A
luciferase reporter plasmid containing the human retinoblastoma
susceptibility (Rb) gene promoter (pRB-luciferase) and expression
plasmids for hGABP
, hGABP
, and hGABP
have also been described
(12). The expression plasmids in fly cells for YEAF1, YEAF1 (CR1OR),
and YAF-2 (A5C
P/YEAF1, A5C
P/YEAF1 (CR1OR), and A5C
P/YAF-2)
were constructed by inserting each DNA fragment into an A5C
P
expression plasmid.
, and actin
cDNA probes as recommended by the manufacturer.
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
Subunit--
In order to understand the mechanism of transcriptional
regulation by E4TF1/hGABP, it is important to clarify the regulatory cross-talk that occurs with other transcription factors and/or cofactors. We used the yeast two-hybrid method to screen a cDNA expression library for genes whose products interact with the non-DNA-binding subunit of E4TF1/hGABP (E4TF1-53/hGABP). We used an amino-terminally truncated form of hGABP
as bait
(LexA-hGABP
-(249-383)) to avoid interaction with the
DNA-binding subunit hGABP
. This fusion product retains the
transactivator and self-association domains (see Fig. 2A).
By screening a HeLa cDNA library, we obtained 33 positive colonies
out of ~1 × 106 transformants. Isolation of the
plasmids and subsequent restriction-digestion analysis of the inserted
cDNAs revealed that all of these plasmids contained a single
cDNA species of 1.1 kb in length. Nucleotide sequencing analysis
revealed that this was a novel cDNA that showed similarity to the
previously identified YY1-associated factor 2 (YAF-2) (26).

View larger version (55K):
[in a new window]
Fig. 1.
Similarity of YEAF1 and YAF-2.
A, the deduced amino acid sequence of YEAF1 and its
comparison with YAF-2. The conserved cysteine residues in the zinc
finger motif are indicated by asterisks. B,
schematic representation of YEAF1 and YAF-2. CR1 and
CR2, conserved region 1 and 2; YEAF1 OR, YEAF1
original region.
and hGABP
but Not with
hGABP
--
Specific binding of YEAF1 to hGABP
was verified by
the yeast two-hybrid assay as monitored by 3-AT sensitivity and by
-galactosidase assay (Fig. 2,
A and B). A GAL4AD-YEAF1 fusion protein
interacted with a LexA fusion protein of full-length hGABP
and an
amino-terminally truncated hGABP
-(249-383) that was used as
bait for two-hybrid screening, indicating that the amino-terminal
ankyrin repeat motifs required for interaction with hGABP
are
dispensable for interaction with YEAF1. A more extensive amino-terminal
deletion mutant, hGABP
-(311-383), no longer associated with
YEAF1 despite retaining the leucine zipper-like structure required for
homodimerization and transactivation. These results indicate that a
region of hGABP
spanning amino acids 249-310 is required for
association with YEAF1. Accordingly, hGABP
, an alternatively spliced
form of hGABP
that retains this region but lacks the abilities to
form homodimer and to transactivate, was able to interact with
YEAF1.

View larger version (47K):
[in a new window]
Fig. 2.
Interaction of YEAF1 with hGABP and YY1.
A, schematic structure of the hGABP subunits and the
deletion mutants used for the yeast two-hybrid interaction assay.
Previously identified structural motifs such as the ankyrin repeat
motif (Ank-repeat), leucine zipper structure (Leu
zipper), and nuclear localization signal (NLS) are
shown. B, yeast two-hybrid interaction assay. Yeast strains
doubly transformed with the indicated LexA fusion and GAL4-activation
domain (AD) fusion plasmids were tested for growth on
culture plates in the presence or absence of 3-aminotriazole
(3-AT) (left panel) or for
-galactosidase
(
-gal) activity (right panel).
did
not interact with GAL4AD-YEAF1, although it did interact with
GAL4AD-hGABP
(data not shown). Furthermore, we could not detect an
interaction of YEAF1 with the unrelated ATF1 transcription factor (Fig.
2B) nor with the
- and
-subunits of casein kinase II
(data not shown). These results indicate that YEAF1 specifically interacts with hGABP
.
and YY1. From these observations, we
designated this protein YEAF1 (for YY1- and
E4TF1/hGABP-associated factor-1).
Associates with Both YEAF1 and YAF-2--
We next
determined the domain of YEAF1 that is required for association with
hGABP
. A series of deletion mutants of YEAF1 were fused to GAL4AD
and were assayed for interaction with LexA-hGABP
in yeast (Fig.
3A). As was evident by both
3-AT sensitivity and by
-galactosidase assays (Fig. 3B),
the carboxyl-terminal conserved region 2 (CR2) of YEAF1 was necessary
for interaction with hGABP
.

View larger version (49K):
[in a new window]
Fig. 3.
Both YEAF1 and YAF-2 interact with hGABP
.
A, YEAF1 mutants and YAF-2, shown schematically, were fused
to a GAL4-activation domain for the interaction assay. B,
the 3-AT sensitivity (left panel) and
-galactosidase
activity (right panel) of yeast strains expressing the
indicated fusion constructs. WT, wild type.
. As expected, we were able to detect the interaction of the GAL4AD-YAF-2 and LexA-hGABP
fusion proteins by a yeast two-hybrid assay (Fig. 3B). Therefore, YEAF1 and YAF-2
constitute a protein family that specifically interacts with the hGABP
transcription factor.
and
hGABP
--
We next analyzed the kinetics of the hGABP
and YEAF1
interaction using surface plasmon resonance (SPR). A purified
recombinant GST fusion protein with full-length YEAF1 (GST-YEAF1) was
immobilized onto the sensor chip surface via a previously coupled
anti-GST antibody. By injecting purified recombinant hGABP
protein
at various concentrations into the immobilized or control sensor chips,
we measured real time SPR at the association and dissociation phases of
interaction of hGABP
and YEAF1. Fig.
4A shows the sensorgrams obtained by subtracting the background values. The specific interaction of hGABP
and YEAF1 was dose-dependent, indicating that
hGABP
and YEAF1 bind directly in vitro. From these
sensorgrams, the kd,
ka, and KD values of
the hGABP
/YEAF1 interaction were calculated (Fig. 4B) and
are summarized in Fig. 4C, together with values previously
obtained using hGABP
and hGABP
(8). The equilibrium dissociation
constant (KD) value of hGABP
and YEAF1 was
8.0 × 10
9 M, which is about 10 times
higher than the KD value for the hGABP
and
hGABP
subunits.

View larger version (28K):
[in a new window]
Fig. 4.
Kinetic analysis of hGABP-YEAF1 interaction
using the SPR system. A, sensorgrams obtained by a
sensor chip immobilized with 2500 resonance units of GST-YEAF-1 protein
and various concentrations of recombinant hGABP
solution.
B, plots of ks against
concentration of hGABP
calculated from the sensorgram. The slope
value in a plot of ln(dR/dt) against t (time) is
expressed as
ks, where R is the
resonance unit. The slope gives the association rate constant.
C, kinetic parameters of the interaction of YEAF1 with
hGABP
and hGABP
determined by SPR analyses. The previously
determined values for the interaction of hGABP
with hGABP
and
with its recognition DNA sequence are shown for comparison (8).
and YEAF1 in a
similar manner, and we obtained a similar KD value (3.7 × 10
9 M) (Fig. 4C and
data not shown).
or YY1 in
vivo, we first constructed an expression plasmid containing FLAG-tagged full-length YEAF1 protein and transfected the plasmid into
HeLa cells. Immunofluorescent staining of the transfected cells with an
anti-FLAG antibody revealed that the FLAG-YEAF1 protein is
predominantly localized in the nucleus (data not shown). Similar
nuclear staining was observed when using COS-1 cells transfected with a
full-length YEAF1 expression plasmid (without the tag) and anti-YEAF1
antiserum (data not shown). Nuclear localization of YEAF1 seems quite
reasonable because both hGABP and YY1 are nuclear transcription factors.
, and anti-YY1 antisera. As shown in Fig.
5, both hGABP
and YY1 were detected in
the anti-FLAG precipitate but not in the control precipitate,
demonstrating that YEAF1 forms a complex with both hGABP
and YY1 in
the nucleus.

View larger version (20K):
[in a new window]
Fig. 5.
Interaction of YEAF1 with
hGABP
and YY1 in vivo.
HeLa cells were transfected with expression vectors for FLAG peptide
(
) or FLAG-YEAF1 (+). Total cell extracts (input) or the
fractions immunoprecipitated by an anti-FLAG antibody (ppt)
were immunoblotted with the antibodies indicated at the
left.

View larger version (35K):
[in a new window]
Fig. 6.
Ternary complex formation of hGABP, YEAF1,
and YY1. A, schematic representation of a yeast
three-hybrid assay. Expression level of the Bridge protein can be
controlled by addition of methionine (+Met) into the medium.
DB-fusion, GAL4-DNA-binding domain (DB) fusion; AD- fusion,
GAL4-activation domain (AD) fusion. B,
-galactosidase (
-gal) activity of yeast strains
expressing the indicated fusion and bridge proteins.
-galactosidase activity was relatively high because
full-length hGABP
was fused to the GAL4DB, and we could see no
evidence for interaction of the GAL4DB-hGABP
with the GAL4AD-YY1
(Fig. 6B, lane 1). Co-expression of an intact
YEAF1 protein resulted in significant
-galactosidase expression, and reduction of the YEAF1 expression level by addition of methionine resulted in decrease of the
-galactosidase activity (Fig.
6B, lanes 2 and 3). These results
indicate that these three proteins form a ternary complex in yeast.
, hGABP
, and YEAF1 form a ternary
complex (Fig. 6B, lanes 4-6). These results
together suggest that hGABP
, hGABP
, YEAF1, and YY1 form a
complex, and YEAF1 acts as a bridging factor of the hGABP and YY1
transcription factors.
alone had little effect on
pRb-luciferase reporter activity (Fig. 7B, lanes 1 and 2), whereas co-expression of the hGABP
subunit (but not
the hGABP
subunit) resulted in significant activation of luciferase
activity (Fig. 7B, lanes 5 and 8).
Noticeably, co-transfection of an increasing amount of YEAF1 expression
plasmid together with hGABP
and hGABP
resulted in a
dose-dependent decrease of luciferase activity (Fig. 7B, lanes 9 and 10), indicating that
YEAF1 acts as a transcriptional co-repressor. The repressive effect was
not observed when a YEAF1 mutant defective in hGABP
binding
(CR1OR, see Fig. 3A) was used (Fig. 7B,
lanes 11 and 12). Instead, we reproducibly observed an
increase of the luciferase activity. Possible explanation for this
result will be discussed below.

View larger version (27K):
[in a new window]
Fig. 7.
Distinct transcriptional effects of YEAF1 and
YAF-2 on E4TF1. A, schematic structure of the
luciferase reporter construct containing the Rb promoter
(pRB-luciferase). B, Schneider's 2 cells co-transfected
with pRB-luciferase (0.7 µg), A5C
P-
-galactosidase (0.3 µg),
and empty vector (lane 1) or expression vector for hGABP
(0.6 µg) (lanes 2-12) in combination with expression
vector (0.6 µg) for hGABP
(lanes 5-7) or for hGABP
(lanes 8-12). The transfection mixture (total 4 µg) also
contained an increasing amount (0.6 or 1.8 µg) of expression vector
for YEAF1 (lanes 3, 4, 6, 7, 9, and 10) or its
deletion mutant YEAF1 (CR1OR) (lanes 11 and 12).
Transfection efficiencies were normalized with
-galactosidase
activity, and the data represent the average of three independent
experiments. C, luciferase activities of pRB-luciferase (0.7 µg) in Schneider's 2 cells co-transfected with expression vector for
hGABP
(0.6 µg) and hGABP
(0.6 µg) in combination with an
increasing amount (0.6 or 1.8 µg) of the expression vector for
YAF-2.
--
We next
examined mRNA expression of YEAF1, YAF-2, and
hGABP
in various tissues using specific DNA probes. A
YEAF1 mRNA of about 5 kb was detected in all the tissues
we examined, with the highest expression level in placenta (Fig.
8, top panel). Consistent with
a previous report that YAF-2 is expressed in muscle cells (26), YAF-2 mRNA expression was the highest in heart and
skeletal muscle (Fig. 8, 2nd panel). As we had mentioned
previously (8), hGABP
mRNA was expressed ubiquitously
(Fig. 8, 3rd panel). The expression level of
hGABP
mRNA was the highest in placenta, heart, and
skeletal muscle, where YEAF1 or YAF-2 mRNA
were also highly expressed. Although more detailed expression profiling
is necessary, these results support the idea that YEAF1 and YAF-2 are
tissue-specific cofactors for the hGABP transcription factor.

View larger version (55K):
[in a new window]
Fig. 8.
Tissue distribution of mRNAs for YEAF1,
YAF-2, and E4TF1. Poly(A)+ RNAs isolated from various
human tissues were blotted and hybridized with 32P-labeled
probes specific for YEAF1 (top panel), YAF-2 (2nd
panel), hGABP
/
(3rd panel), and actin
(bottom panel).
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
.
. Although the YEAF1 interaction domain of hGABP
overlaps with the transactivator domain, a more detailed domain analysis may
reveal an active repressor domain. Alternatively, YEAF1 may not be able
to recruit PcG to hGABP and may reduce the transcriptional activity of
hGABP by competition with co-activators such as p300/CBP for binding to
hGABP. These two possible mechanisms are not mutually exclusive, and
further analysis is necessary to fully understand the molecular
mechanism of transcriptional repression by YEAF1.
,
YAF-2 activated hGABP transcriptional activity and YEAF1 repressed it.
As far as we know, YEAF1 and YAF-2 are the only structurally related
transcriptional cofactors that have opposite functions. It has been
reported that the carboxyl-terminal regions of RYBP/YEAF1, OR and CR2,
are necessary for transcriptional repressor function. YAF-2 may lack
the ability to repress transcription because it lacks the OR domain,
and its CR2 region is relatively divergent. If this is the case, one
possible explanation for the opposite functions of YEAF1 and YAF-2 is
that YAF-2 lacks the ability to bind to PcG complexes. Alternatively,
YAF-2 may have an intrinsic transactivation domain. It should be noted
that co-expression with hGABP of a truncated YEAF1 protein (CR1OR) that
lacks CR2 and the ability to bind to hGABP resulted in an increase of
Rb promoter activity (Fig. 7). This mutant YEAF1 may compete for binding to endogenous YEAF1 with PcG complexes, which may lead to
accumulation of non-functional PcG complexes and to the activation of
transcriptional activity.
![]()
ACKNOWLEDGEMENTS
![]()
FOOTNOTES
Present address: Dept. of Biological Chemistry and Molecular
Pharmacology, Harvard Medical School, 240 Longwood Ave., Boston, MA 02115.
![]()
ABBREVIATIONS
![]()
REFERENCES
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
1.
Watanabe, H.,
Imai, T.,
Sharp, P. A.,
and Handa, H.
(1988)
Mol. Cell. Biol.
8,
1290-1300 2.
Watanabe, H.,
Wada, T.,
and Handa, H.
(1990)
EMBO J.
9,
841-847[Medline]
[Order article via Infotrieve]
3.
Watanabe, H.,
Sawada, J.-i.,
Yano, K.,
Yamaguchi, K.,
Goto, M.,
and Handa, H.
(1993)
Mol. Cell. Biol.
13,
1385-1391 4.
Sawada, J.-i.,
Goto, M.,
Sawa, C.,
Watanabe, H.,
and Handa, H.
(1994)
EMBO J.
13,
1396-1402[Medline]
[Order article via Infotrieve]
5.
LaMarco, K.,
Thompson, C. C.,
Byers, B. P.,
Walton, E. M.,
and McKnight, S. L.
(1991)
Science
253,
789-792 6.
Thompson, C. C.,
Brown, T. A.,
and McKnight, S. L.
(1991)
Science
253,
762-768 7.
Sawa, C.,
Goto, M.,
Suzuki, F.,
Watanabe, H.,
Sawada, J.-i.,
and Handa, H.
(1996)
Nucleic Acids Res.
24,
4954-4961 8.
Suzuki, F.,
Goto, M.,
Sawa, C.,
Ito, S.,
Watanabe, H.,
Sawada, J.-i.,
and Handa, H.
(1998)
J. Biol. Chem.
273,
29302-29308 9.
Virbasius, J. V.,
Virbasius, C. A.,
and Scarpulla, R. C.
(1993)
Genes Dev.
7,
380-392 10.
Villena, J. A.,
Vinas, O.,
Mampel, T.,
Iglesias, R.,
Giralt, M.,
and Villarroya, F.
(1998)
Biochem. J.
331,
121-127[Medline]
[Order article via Infotrieve]
11.
Genuario, R. R.,
Kelley, D. E.,
and Perry, R. P.
(1993)
Gene Expr.
3,
279-288[Medline]
[Order article via Infotrieve]
12.
Sowa, Y.,
Shiio, Y.,
Fujita, T.,
Matsumoto, T.,
Okuyama, Y.,
Kato, D.,
Inoue, J.,
Sawada, J.-i.,
Goto, M.,
Watanabe, H.,
Handa, H.,
and Sakai, T.
(1997)
Cancer Res.
57,
3145-3148 13.
Savoysky, E.,
Mizuno, T.,
Sowa, Y.,
Watanabe, H.,
Sawada, J.-i.,
Nomura, H.,
Ohsugi, Y.,
Handa, H.,
and Sakai, T.
(1994)
Oncogene
9,
1839-1846[Medline]
[Order article via Infotrieve]
14.
Yokomori, N.,
Kobayashi, R.,
Moore, R.,
Sueyoshi, T.,
and Negishi, M.
(1995)
Mol. Cell. Biol.
15,
5355-5362[Abstract]
15.
Rosmarin, A. G.,
Caprio, D. G.,
Kirsch, D. G.,
Handa, H.,
and Simkevich, C. P.
(1995)
J. Biol. Chem.
270,
23627-23633 16.
Nuchprayoon, I.,
Simkevich, C. P.,
Luo, M.,
Friedman, A. D.,
and Rosmarin, A. G.
(1997)
Blood
89,
4546-4554 17.
Avots, A.,
Hoffmeyer, A.,
Flory, E.,
Cimanis, A.,
Rapp, U. R.,
and Serfling, E.
(1997)
Mol. Cell. Biol.
17,
4381-4389[Abstract]
18.
Khurana, T. S.,
Rosmarin, A. G.,
Shang, J.,
Krag, T. O.,
Das, S.,
and Gammeltoft, S.
(1999)
Mol. Biol. Cell
10,
2075-2086 19.
Gramolini, A. O.,
Angus, L. M.,
Schaeffer, L.,
Burton, E. A.,
Tinsley, J. M.,
Davies, K. E.,
Changeux, J. P.,
and Jasmin, B. J.
(1999)
Proc. Natl. Acad. Sci. U. S. A.
96,
3223-3227 20.
Schaeffer, L.,
Duclert, N.,
Huchet-Dymanus, M.,
and Changeux, J. P.
(1998)
EMBO J.
17,
3078-3090[CrossRef][Medline]
[Order article via Infotrieve]
21.
Sawada, J.-i.,
Simizu, N.,
Suzuki, F.,
Sawa, C.,
Goto, M.,
Hasegawa, M.,
Imai, T.,
Watanabe, H.,
and Handa, H.
(1999)
J. Biol. Chem.
274,
35475-35482 22.
Rosmarin, A. G.,
Luo, M.,
Caprio, D. G.,
Shang, J.,
and Simkevich, C. P.
(1998)
J. Biol. Chem.
273,
13097-13103 23.
Galvagni, F.,
Capo, S.,
and Oliviero, S.
(2001)
J. Mol. Biol.
306,
985-996[CrossRef][Medline]
[Order article via Infotrieve]
24.
Vogel, J. L.,
and Kristie, T. M.
(2000)
EMBO J.
19,
683-690[CrossRef][Medline]
[Order article via Infotrieve]
25.
Morii, E.,
Ogihara, H.,
Oboki, K.,
Sawa, C.,
Sakuma, T.,
Nomura, S.,
Esko, J. D.,
Handa, H.,
and Kitamura, Y.
(2001)
Blood
97,
3032-3039 26.
Kalenik, J. L.,
Chen, D.,
Bradley, M. E.,
Chen, S. J.,
and Lee, T. C.
(1997)
Nucleic Acids Res.
25,
843-849 27.
Fields, S.,
and Song, O.
(1989)
Nature
340,
245-246[CrossRef][Medline]
[Order article via Infotrieve]
28.
Shi, Y.,
Seto, E.,
Chang, L. S.,
and Shenk, T.
(1991)
Cell
67,
377-388[CrossRef][Medline]
[Order article via Infotrieve]
29.
Garcia, E.,
Marcos-Gutierrez, C.,
del Mar Lorente, M.,
Moreno, J. C.,
and Vidal, M.
(1999)
EMBO J.
18,
3404-3418[CrossRef][Medline]
[Order article via Infotrieve]
30.
Brown, J. L.,
Mucci, D.,
Whiteley, M.,
Dirksen, M. L.,
and Kassis, J. A.
(1998)
Mol. Cell
1,
1057-1064[CrossRef][Medline]
[Order article via Infotrieve]
31.
Satijn, D. P.,
Hamer, K. M.,
den Blaauwen, J.,
and Otte, A. P.
(2001)
Mol. Cell. Biol.
21,
1360-1369 32.
Trimarchi, J. M.,
Fairchild, B.,
Wen, J.,
and Lees, J. A.
(2001)
Proc. Natl. Acad. Sci. U. S. A.
98,
1519-1524 33.
Vassias, I.,
Hazan, U.,
Michel, Y.,
Sawa, C.,
Handa, H.,
Gouya, L.,
and Morinet, F.
(1998)
J. Biol. Chem.
273,
8287-8293 34.
Lenka, N.,
Vijayasarathy, C.,
Mullick, J.,
and Avadhani, N. G.
(1998)
Prog. Nucleic Acids Res. Mol. Biol.
61,
309-344[Medline]
[Order article via Infotrieve]
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
I. Gonzalez, R. Aparicio, and A. Busturia Functional Characterization of the dRYBP Gene in Drosophila Genetics, July 1, 2008; 179(3): 1373 - 1388. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. S. Santiago, H. Ishii, S. Shafi, R. Khurana, P. Kanellakis, R. Bhindi, M. J. Ramirez, A. Bobik, J. F. Martin, C. N. Chesterman, et al. Yin Yang-1 Inhibits Vascular Smooth Muscle Cell Growth and Intimal Thickening by Repressing p21WAF1/Cip1 Transcription and p21WAF1/Cip1-Cdk4-Cyclin D1 Assembly Circ. Res., July 20, 2007; 101(2): 146 - 155. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. E. Stanton, L. J. McReynolds, T. Evans, and N. Schreiber-Agus Yaf2 Inhibits Caspase 8-mediated Apoptosis and Regulates Cell Survival during Zebrafish Embryogenesis J. Biol. Chem., September 29, 2006; 281(39): 28782 - 28793. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. K. Pirity, J. Locker, and N. Schreiber-Agus Rybp/DEDAF Is Required for Early Postimplantation and for Central Nervous System Development Mol. Cell. Biol., August 15, 2005; 25(16): 7193 - 7202. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Delehouzee, T. Yoshikawa, C. Sawa, J.-i. Sawada, T. Ito, M. Omori, T. Wada, Y. Yamaguchi, Y. Kabe, and H. Handa GABP, HCF-1 and YY1 are involved in Rb gene expression during myogenesis Genes Cells, July 1, 2005; 10(7): 717 - 731. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Zheng, B. Patel, M. McMenamin, A. M. Paprocki, R. D. Schramm, N. G. Nagl Jr, D. Wilsker, X. Wang, E. Moran, and K. E. Latham Expression of Genes Encoding Chromatin Regulatory Factors in Developing Rhesus Monkey Oocytes and Preimplantation Stage Embryos: Possible Roles in Genome Activation Biol Reprod, May 1, 2004; 70(5): 1419 - 1427. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. J. Gordon, S. Saleque, and B. K. Birshtein Yin Yang 1 Is a Lipopolysaccharide-Inducible Activator of the Murine 3' Igh Enhancer, hs3 J. Immunol., June 1, 2003; 170(11): 5549 - 5557. [Abstract] [Full Text] [PDF] |